Ingevity Corporation
General ticker "NGVT" information:
- Sector: Materials
- Industry: Chemicals - Specialty
- Capitalization: $2.0B (TTM average)
Ingevity Corporation follows the US Stock Market performance with the rate: 57.2%.
Estimated limits based on current volatility of 1.8%: low 66.82$, high 69.24$
Factors to consider:
- Total employees count: 1600 as of 2024
- China accounted for 13.1% of revenue in the fiscal year ended 2024-12-31
- US accounted for 52.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key customers, Cybersecurity threats, Geopolitical risks, Labor/talent shortage/retention, Environmental regulations
- Price in estimated range
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [48.64$, 75.62$]
- 2026-12-31 to 2027-12-31 estimated range: [47.41$, 74.53$]
Financial Metrics affecting the NGVT estimates:
- Negative: with PPE of 13.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: Operating cash flow per share per price, % of 15.41 > 12.90
- Positive: -0.03 < Industry operating cash flow per share per price (median), % of 5.08
- Positive: -4.41 < Investing cash flow per share per price, % of -2.67
- Negative: negative Net income
- Positive: -9.55 < Industry operating profit margin (median), % of 2.39
- Positive: 0.05 < Industry earnings per price (median), % of 2.55
Short-term NGVT quotes
Long-term NGVT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,692.10MM | $1,406.40MM | $1,069.50MM |
| Operating Expenses | $1,435.70MM | $1,146.50MM | $1,211.60MM |
| Operating Income | $256.40MM | $259.90MM | $-142.10MM |
| Non-Operating Income | $-266.50MM | $-795.50MM | $0.00MM |
| Interest Expense | $93.30MM | $97.80MM | $73.10MM |
| R&D Expense | $31.80MM | $28.10MM | $28.40MM |
| Income(Loss) | $-10.10MM | $-535.60MM | $-142.10MM |
| Taxes | $-4.70MM | $-105.30MM | $8.20MM |
| Other Income(Loss) | $-111.20MM | $-308.90MM | $-16.80MM |
| Net Income(Loss)* | $-5.40MM | $-430.30MM | $-167.10MM |
| Stockholders Equity | $631.40MM | $195.20MM | $29.70MM |
| Inventory | $308.80MM | $226.80MM | $186.00MM |
| Assets | $2,623.30MM | $2,022.60MM | $1,651.10MM |
| Operating Cash Flow | $205.10MM | $128.60MM | $331.20MM |
| Capital expenditure | $109.80MM | $77.60MM | $57.70MM |
| Investing Cash Flow | $-77.30MM | $-79.50MM | $-57.50MM |
| Financing Cash Flow | $-99.90MM | $-70.20MM | $-252.20MM |
| Earnings Per Share** | $-0.15 | $-11.85 | $-4.62 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.